hepat
c
affect
world
popul
yet
current
treatment
option
limit
interferonribavirin
drug
regimen
achiev
cure
rate
depend
hepat
c
viru
hcv
genotyp
besid
extens
screen
hcvspecif
compound
wellestablish
medicin
drug
recent
demonstr
antihcv
effect
hcv
replicon
cell
one
drug
arbidol
arb
russianmad
broad
spectrum
antivir
agent
previous
shown
inhibit
acut
chronic
hcv
infect
show
arb
inhibit
cell
entri
hcv
pseudoparticl
genotyp
dosedepend
fashion
arb
also
display
dosedepend
inhibit
hcv
membran
fusion
assay
use
hcv
pseudoparticl
hcvpp
fluoresc
liposom
arb
inhibit
hcvpp
fusion
found
effect
genotyp
genotyp
vitro
biochem
studi
reveal
arb
associ
membranelik
environ
deterg
lipid
membran
associ
particularli
promin
acid
ph
optim
hcvmediat
fusion
result
suggest
affin
arb
lipid
membran
could
account
antihcv
action
togeth
differenti
level
interact
key
motif
hcv
glycoprotein
differ
genotyp
hepat
c
viru
hcv
infect
estim
million
world
popul
hepat
c
frequent
indic
liver
transplant
current
treatment
option
limit
pegyl
recombin
interferon
alpha
combin
ribavirin
howev
viremia
erad
variabl
achiev
depend
genotyp
viru
erad
genotyp
patient
clearli
problem
north
america
europ
japan
genotyp
preval
genotyp
hcv
work
support
anr
agenc
national
de
recherch
sur
le
sida
et
le
hepatit
viral
eip
therefor
appear
resist
ifn
antivir
therapi
like
due
factor
viral
origin
histor
develop
new
antihcv
drug
hamper
due
lack
cell
cultur
small
anim
model
requir
preclin
evalu
antivir
compound
gener
hcv
replicon
system
afford
massiv
antivir
drug
screen
effort
distinct
specif
antihcv
compound
target
key
viral
function
group
broadspectrum
medicin
drug
origin
design
treatment
target
toward
virus
use
replicon
system
compound
shown
possess
potent
antivir
activ
toward
hcv
advantag
group
antivir
alreadi
met
pharmacolog
criteria
medicin
drug
alreadi
approv
clinic
use
countri
one
compound
russianmad
arbidol
arb
acid
dimethylamino
methyl
phenylthio
methyl
ethyl
ester
monohydrochlorid
ca
registri
number
fig
origin
describ
antiinfluenza
drug
purport
immunostimul
properti
arb
licens
sever
year
russia
use
prophylaxi
treatment
influenza
b
infect
allegedli
exert
effect
activ
macrophag
phagocyt
activ
may
also
stimul
aspect
cellular
humor
immun
arb
inhibit
influenza
virusinduc
membran
fusion
may
capac
induc
serum
interferon
recent
studi
extend
inhibitori
activ
human
virus
respiratori
syncyti
viru
parainfluenza
viru
rhinoviru
hepat
b
viru
bird
virus
avian
coronaviru
influenza
viru
shown
sensit
arb
well
recent
demonstr
arb
inhibit
acut
chronic
hcv
infect
vitro
hcv
replic
use
hcv
replicon
system
current
studi
character
arb
mechan
action
present
detail
biochem
character
arb
interact
membran
examin
arb
inhibit
hcv
entri
use
hcv
pseudoparticl
hcvpp
found
arb
inhibit
infect
cell
hcvpp
differ
genotyp
inhibit
hcvppmediat
membran
fusion
inhibit
particularli
promin
acid
ph
optim
arb
associ
membran
sodium
dodecyl
sulfat
sd
dm
phosphatidylcholin
egg
yolk
pc
pure
cholesterol
chol
pure
triton
purchas
sigma
phosphatidylserin
ps
porcin
brain
avanti
polar
lipid
alabast
al
octadecyl
rhodamin
b
chlorid
r
molecular
probe
arbidol
arb
acid
dimethylamino
methyl
phenylthio
methyl
ethyl
ester
monohydrochlorid
kind
gift
schuster
ia
leneva
arb
first
dissolv
absolut
ethanol
complet
final
concentr
mm
steril
twicedistil
water
final
concentr
ethanol
contact
membran
vari
cmvgagpol
murin
leukemia
viru
mlv
packag
construct
encod
mlv
gag
pol
gene
mlvgfp
plasmid
encod
mlvbase
transfer
vector
contain
cmvgfp
intern
transcript
unit
describ
previous
phcmvha
na
express
vector
encod
hemagglutinin
neuraminidas
fowl
plagu
viru
respect
encod
hcv
glycoprotein
genotyp
strain
genotyp
clone
genotyp
isol
phcmvrd
express
vector
encod
felin
endogen
oncoretroviru
glycoprotein
pseudoparticl
bear
either
envelop
glycoprotein
hcv
hcvpp
hemagglutinin
influenza
viru
happ
envelop
protein
gener
purifi
previous
describ
infect
cell
concentr
pseudoparticl
perform
absenc
presenc
increas
concentr
arb
ad
cell
cultur
medium
ethanol
water
stock
solut
arb
ad
cell
increas
concentr
similar
volum
either
pseudoparticl
bind
step
cell
cultur
medium
remov
replac
fresh
medium
infect
assess
later
fac
analysi
valu
obtain
hcvpp
untreat
cell
taken
pc
chol
molar
ratio
ps
larg
unilamellar
vesicl
nm
prepar
describ
r
label
ps
liposom
ad
unlabel
ps
vesicl
pb
unlabeledlabel
ratio
min
equilibr
cacl
ad
final
mm
ca
concentr
initi
membran
fusion
similar
experi
perform
presenc
arbidol
arb
spectral
properti
investig
spectrophotometri
spectrofluorimetri
phosphatebuff
salin
pb
ph
absenc
presenc
deterg
micel
liposom
spectral
properti
indol
deriv
tryptophan
arb
see
depend
microenviron
turn
influenc
maximum
posit
max
quantum
yield
fluoresc
fluoresc
record
slm
aminco
fluorimet
excit
slit
set
nm
emiss
slit
nm
excit
polar
orient
rel
vertic
emiss
improv
spectral
resolut
fluoresc
minim
scatter
effect
spectra
measur
use
quartz
cuvett
emiss
spectra
collect
nm
region
increment
nm
correct
vesicl
light
scatter
increas
quantum
yield
given
ff
f
f
denot
fluoresc
nm
addit
deterg
liposom
respect
measur
fusion
pseudoparticl
liposom
base
upon
lipid
mix
assay
describ
detail
elsewher
arb
preincub
min
either
pseudoparticl
liposom
lipid
mix
initi
decreas
ph
sought
determin
whether
arb
effect
hcv
entri
name
whether
arb
could
affect
infect
cultur
cell
hcvpp
result
experi
present
figur
happ
use
control
arb
present
cours
hcvpp
infect
decreas
infect
observ
hcv
genotyp
test
inhibit
effect
proport
arb
concentr
maxim
reduct
inhibit
infect
observ
arb
hcvpp
preincub
arb
infect
subsequ
continu
arb
presenc
infect
dosedepend
inhibit
infect
observ
genotyp
test
maximum
inhibit
arb
pronounc
inhibit
seen
cell
preincub
arb
left
presenc
arb
onward
condit
inhibit
achiev
arb
infect
reduc
arb
inhibit
genotyp
even
genotyp
happ
behav
similar
way
show
dosedepend
decreas
infect
b
c
maxim
arb
effect
inhibit
note
drastic
reduct
infect
inhibit
could
also
observ
cell
preincub
overnight
arb
toxic
observ
data
shown
convers
cell
infect
unaffect
presenc
arb
whatev
drug
concentr
test
whatev
infect
condit
design
suggest
arb
might
achiev
certain
level
specif
toward
viral
glycoprotein
particular
name
hcv
influenza
glycoprotein
studi
interestingli
cell
preincub
arb
drug
remov
cell
immedi
hcvpp
infect
signific
effect
hcvpp
infect
observ
although
note
reduct
infect
happ
highest
concentr
arb
taken
togeth
data
indic
arb
exert
inhibitori
effect
infect
physic
contact
either
pseudoparticl
cell
membran
promin
acid
ph
absenc
infect
inhibit
observ
arb
withdraw
incub
medium
infect
suggest
transient
accumul
cell
surfac
andor
intracellular
compart
enough
exert
sustain
hcv
inhibitori
action
effect
arb
hcvppmediat
fusion
role
ph
next
directli
test
vitro
lipid
mix
assay
effect
arbidol
hcvpp
membran
fusion
activ
present
figur
decreas
ph
rapid
signific
dequench
observ
measur
lipid
mix
hcvpp
r
label
liposom
genotyp
see
also
presenc
arb
hcvpp
fusion
abil
inhibit
inhibit
directli
proport
arb
concentr
variat
among
hcv
genotyp
though
inde
promin
inhibit
fusion
arb
observ
genotyp
fusion
complet
abolish
arb
convers
similar
block
fusion
achiev
arb
genotyp
genotyp
measur
fusion
still
observ
concentr
observ
reproduc
n
reason
differ
fusion
behaviour
genotyp
present
unclear
arb
concentr
higher
test
avoid
toxic
cell
note
also
immunoblot
analys
glycoprotein
reveal
present
viral
prepar
data
shown
also
control
global
input
differ
pseudoparticl
estim
amount
mlv
core
protein
viral
prepar
immunoblot
amount
core
similar
pseudoparticl
prepar
assay
fusion
data
shown
suggest
arb
might
differenti
interact
hcv
glycoprotein
differ
genotyp
see
discuss
note
fusion
mediat
could
investig
assay
sinc
glycoprotein
activ
fusion
phindepend
receptordepend
manner
data
shown
inhibit
fusion
arb
compar
arb
preincub
hcvpp
liposom
data
shown
arbinduc
inhibit
also
depend
upon
lipid
composit
liposom
sinc
similar
hcv
fusion
inhibit
observ
plain
pc
shown
pc
chol
liposom
fig
next
ask
whether
arb
could
inhibit
fusion
membran
system
well
therefor
investig
arb
effect
toward
cainduc
fusion
ps
liposom
kinet
ps
vesicl
lipid
mix
ca
compar
neutral
acid
ph
previous
report
presenc
arb
inhibit
lipid
mix
observ
ph
pronounc
effect
acid
neutral
ph
arb
spectral
properti
affect
ca
data
shown
rule
direct
interact
arb
ca
would
artifactu
lead
fusion
inhibit
altogeth
result
suggest
arb
membran
fusion
inhibitor
exert
effect
viral
proteininduc
fusion
proteinfre
membran
fusion
system
thu
arb
might
associ
membran
exert
inhibitori
effect
howev
probabl
mode
action
sinc
hcvpp
differ
genotyp
differenti
sensit
antivir
effect
arb
ii
contrast
ha
hcv
envelop
protein
sensit
arb
observ
suggest
arb
might
differenti
interact
key
motif
hcv
fusion
protein
sequenc
might
differ
among
hcv
genotyp
moreov
arb
act
predominantli
low
ph
vitro
fusion
assay
two
hypothes
might
explain
behaviour
arb
could
block
fusion
either
counteract
acidif
process
similarli
chloroquin
andor
proton
form
low
ph
see
proton
form
substitut
indol
sinc
cainduc
ps
liposom
fusion
system
phdepend
markedli
inhibit
arb
low
ph
first
hypothesi
arb
block
endosom
acidif
explan
arbinduc
fusion
inhibit
deem
unlik
nonetheless
sinc
arb
weak
base
fig
test
hypothesi
directli
end
increas
concentr
arb
ad
suspens
hcvpp
liposom
pb
ph
equilibr
exactli
measur
volum
dilut
hcl
requir
decreas
ph
ad
tube
ph
record
ph
meter
within
test
rang
arb
concentr
could
detect
slight
ph
variat
ph
unit
data
shown
narrow
ph
rang
alter
could
critic
influenza
virusinduc
fusion
happ
unlik
affect
broadspectrum
ph
fusogen
properti
hcv
therefor
result
essenti
rule
direct
buffer
role
arb
explan
fusion
inhibit
behaviour
arb
low
ph
examin
detail
next
paragraph
arb
indol
deriv
share
structur
tryptophan
trp
prefer
indol
deriv
membran
interfac
specif
trp
membran
protein
well
document
interfaci
prefer
relat
flat
rigid
structur
molecul
aromat
allow
establish
interact
lipid
headgroup
ie
interact
indol
ring
cloud
nitrogen
lipid
headgroup
therefor
reason
arb
might
behav
similar
way
ie
might
enter
similar
interact
indol
group
n
ch
group
phosphatidylcholin
order
investig
arb
behaviour
toward
membran
first
analyz
spectral
properti
solut
light
absorpt
properti
studi
spectrophotometri
nm
wavelength
rang
arb
absorb
peak
nm
exc
nm
ph
dot
line
ph
data
shown
former
exc
use
excit
wavelength
studi
arb
fluoresc
properti
sinc
reason
shorter
excit
wavelength
would
improv
spectral
separ
emiss
scatter
see
also
order
achiev
adequ
signaltonois
ratio
analyz
averag
emiss
spectra
solid
line
pb
ph
arb
display
max
nm
thin
solid
line
max
slightli
blueshift
nm
ph
thick
solid
line
investig
arb
behaviour
toward
membran
membranelik
environ
exc
nm
em
nm
use
unless
otherwis
indic
three
deterg
chosen
membranelik
environ
studi
interact
arb
micel
sodium
dodecyl
sulfat
sd
negativelycharg
dodecylmaltosid
dm
neutral
glucid
natur
zwitterion
lipid
natur
deterg
concentr
well
critic
micellar
concentr
cmc
ph
addit
arb
micel
led
dramat
increas
quantum
yield
fluoresc
deterg
test
fig
tabl
order
dm
sd
effect
even
pronounc
ph
increas
quantum
yield
concomit
moder
blue
shift
maximum
emiss
wavelength
sd
fig
tabl
two
phenomena
indic
associ
arb
micel
accompani
partial
like
superfici
burial
arb
molecul
micel
interact
pronounc
acid
ph
arb
molecul
proton
neutral
ph
suggest
proton
form
arb
probabl
effect
inhibit
membran
fusion
actual
arb
molecul
monitor
bind
arb
ph
increas
concentr
sd
dm
micel
result
fluoresc
chang
nm
result
shown
shape
three
bind
curv
similar
show
bind
similar
case
deterg
studi
steep
increas
fluoresc
observ
till
cmc
valu
deterg
reach
deterg
concentr
cmc
fluoresc
plateau
indic
virtual
arb
molecul
bound
micel
high
deterg
concentr
condit
almost
observ
arb
fluoresc
therefor
due
arb
incorpor
interact
deterg
micel
confirm
affin
tropism
arb
membranelik
environ
particularli
acid
ph
influenc
ph
arb
bind
deterg
micel
studi
use
dm
sole
sinc
deterg
gave
rise
largest
increas
fluoresc
quantum
yield
tabl
neutral
charg
arb
ad
mm
solut
dm
buffer
appear
clearli
arb
fluoresc
increas
ph
decreas
increas
arb
fluoresc
ph
nm
shown
sinc
know
previou
experi
arb
dm
ratio
use
virtual
arb
molecul
bound
micel
observ
fluoresc
increas
ph
decreas
may
aris
differ
arb
ioniz
state
neutral
acid
ph
depend
ph
arb
may
therefor
exist
deproton
neutral
form
proton
cation
form
see
arb
posit
withinon
deterg
micel
intrins
fluoresc
properti
may
depend
ioniz
state
taken
togeth
data
indic
arbidol
tropism
membranelik
environ
propens
interact
hydrophob
environ
pronounc
acid
neutral
ph
possibl
due
ioniz
state
arb
interact
arb
liposom
studi
neutral
acid
ph
result
present
tabl
presenc
increas
concentr
pc
chol
liposom
max
progress
shift
lower
wavelength
blue
shift
concomit
increas
quantum
yield
tabl
chang
like
result
signific
increas
hydrophob
arb
microenviron
upon
bind
liposom
moreov
fluoresc
emiss
depend
upon
phospholipid
concentr
compar
curv
c
panel
indic
arb
microenviron
becom
hydrophob
presenc
liposom
therefor
point
toward
interact
arb
lipid
membran
trend
even
pronounc
acid
ph
tabl
inde
larger
blue
shift
nm
associ
greater
increas
quantum
yield
ph
compar
ph
may
reflect
enhanc
incorpor
arb
molecul
hydrophob
core
lipid
bilay
low
ph
extend
previou
observ
arb
inhibit
fusion
promin
acid
ph
neutral
ph
phindepend
cainduc
ps
vesicl
fusion
model
addit
similar
ph
arb
concentr
much
larger
blue
shift
observ
liposom
deterg
micel
tabl
indic
environ
arb
significantli
hydrophob
lipid
bilay
micel
ie
arb
reach
hydrophob
core
lipid
bilay
wherea
like
associ
shallowli
surfac
deterg
micel
consist
view
fluoresc
indol
moieti
arb
partial
buri
liposom
membran
taken
togeth
data
provid
direct
evid
arb
incorpor
artifici
lipid
bilay
liposom
well
biolog
membran
cellular
viral
membran
indic
arb
inhibit
hcv
entri
cell
hcvmediat
fusion
act
directli
membran
level
studi
aim
assess
antihcv
properti
arbidol
broadspectrum
russianmad
oral
antivir
drug
use
hcv
pseudoparticl
analys
effect
arb
hcv
entri
fusion
step
demonstr
arb
abl
inhibit
process
dosedepend
manner
hcv
entri
membran
fusion
earli
step
lifecycl
viru
hcv
first
interact
envelop
glycoprotein
set
coreceptor
plasma
membran
level
review
eventu
becom
endocytos
due
combin
action
acidif
endosom
particular
lipid
like
cholesterol
viral
fusion
occur
broad
spectrum
ph
rang
suggest
fusion
could
occur
earli
well
late
endosom
least
cascad
reorgan
could
occur
fusion
protein
progress
viru
endocyt
pathway
respect
inhibitori
action
arb
hcvpp
entri
fusion
could
envisag
variou
level
includ
viral
glycoprotein
membran
endosom
lumen
viral
infect
studi
hcvpp
show
arb
exert
inhibitori
effect
present
throughout
cours
infect
almost
complet
inhibit
achiev
cell
preincub
arb
similarli
arb
inhibit
primari
infect
cell
viru
complet
cell
preincub
arb
infect
point
action
arb
cell
membran
suggest
certain
level
membran
impregnationsatur
arb
must
achiev
order
effici
block
hcv
infect
vitro
fusion
complet
block
low
arb
concentr
fusion
inhibit
similarli
viral
envelop
membran
target
liposom
membran
preincub
arb
indic
effect
membran
although
specif
effect
arb
hcv
glycoprotein
exclud
physicochem
point
view
arb
display
tropism
membran
membranelik
environ
deterg
micel
particularli
promin
low
ph
tabl
may
due
arb
indolederiv
structur
moreov
arb
may
interact
lipid
via
hydrophob
aromat
moieti
molecul
concern
deterg
arb
bound
similarli
acid
ph
micel
three
deterg
test
bind
total
c
almost
total
mm
sd
mm
dm
condit
deterg
micellar
form
sinc
cmc
valu
c
sd
dm
mm
mm
respect
enhanc
arb
fluoresc
greater
upon
bind
dm
micel
upon
bind
deterg
micel
lipid
vesicl
tabl
maltos
headgroup
dm
rigid
give
high
cohes
headgroup
region
micel
maltos
ring
might
therefor
exert
stack
effect
indol
ring
arb
lead
observ
dramat
increas
arb
fluoresc
howev
consist
observ
lack
shift
toward
lower
wavelength
blue
shift
arb
fluoresc
dm
micel
low
ph
could
come
shield
effect
proton
arb
play
numer
hydroxyl
group
dm
concern
lipid
vesicl
arb
membran
associ
accompani
blue
shift
increas
quantum
yield
fluoresc
arbtolipid
ratio
test
particularli
promin
low
ph
tabl
compar
data
obtain
deterg
micel
infer
arb
probabl
emb
deepli
lipid
bilay
micel
probabl
hydrophob
microenviron
bilay
micel
differ
fluoresc
behaviour
lipid
bilay
deterg
micel
like
come
low
cmc
lipid
aqueou
buffer
lipid
condens
membran
phase
compar
dm
micel
specif
flexibl
cholin
headgroup
pc
might
allow
better
access
hydrophob
core
particl
vesicl
micel
rigid
sugar
headgroup
dm
alreadi
describ
indol
deriv
tryptophan
octyl
ester
indol
deriv
shown
exhibit
prefer
membran
interfac
due
flat
rigid
structur
molecul
aromat
allow
establish
interact
positivelycharg
quaternari
ammonium
lipid
headgroup
sphenyl
group
arb
could
also
interact
hydrophob
fatti
acid
chain
phospholipid
insid
bilay
amino
group
could
bond
phosphat
moieti
phospholipid
establish
salt
bridg
two
adjac
phospholipid
molecul
ionpair
complex
low
ph
interact
would
favour
due
proton
amino
group
particularli
proton
could
displac
ester
group
indol
plane
place
better
posit
bond
neighbour
molecul
see
could
turn
lead
better
membran
associ
consid
chemic
plausibl
interact
arb
might
propens
intercal
lipid
membran
adopt
consist
orient
fill
gap
lipid
molecul
molar
ratio
arb
lipid
vitro
fusion
assay
ca
plausibl
mode
action
could
format
stabl
dosedepend
arb
cage
surfac
membran
therefor
excess
stabil
membran
becom
resist
fusion
mode
action
would
quit
reminisc
observ
tripeptid
inhibit
fusion
carbobenzoxydphenylalanyllphenylalanylglycin
zffg
zffg
shown
inhibit
viral
fusion
stabil
bilay
lamellar
phase
therebi
inhibit
nonbilay
phase
format
like
surfac
bilay
ie
form
tight
complex
phospholipid
carbobenzoxi
group
import
effect
fusion
inhibit
interest
note
arb
contain
phenylthiomethyl
group
posit
indol
ring
could
play
compar
role
carbobenzoxi
zffg
fusion
inhibit
zffg
inhibit
format
highli
curv
surfac
occur
membran
fusion
found
effect
low
ph
proton
form
tripeptid
predomin
correl
well
arb
behaviour
observ
studi
proton
form
might
well
penetr
deeper
membran
charg
form
hypothesi
membran
stabil
mode
action
arb
viral
fusion
system
find
support
psca
model
system
sinc
arb
also
block
fusion
membran
system
effici
low
neutral
ph
psca
model
also
bring
inform
arb
inhibit
fusion
neutral
ph
could
explan
arb
inhibit
fusion
phindepend
virus
paramyxovirus
coronavirus
viru
level
arb
might
block
uncoat
membran
fusion
process
infect
fusion
data
exclud
direct
action
arb
endosom
ph
andor
hcv
glycoprotein
base
upon
chemic
structur
arb
weak
base
could
undergo
hydrolysi
ester
function
vivo
reason
arb
could
exert
effect
hcvpp
infect
fusion
inhibit
acidif
endosom
andor
accumul
hydrolys
arb
molecul
first
hypothesi
test
directli
measur
ph
liposomehcvpp
suspens
condit
fusion
assay
even
high
arb
concentr
could
detect
signific
variat
ph
behaviour
arb
ionophor
blocker
proton
pump
insid
endosom
exclud
vivo
howev
effect
oper
would
unlik
predomin
mechan
action
molecul
sinc
arb
inhibit
phdepend
phindepend
virus
similar
efficaci
show
studi
arb
could
block
fusion
phindepend
cainduc
ps
vesicl
fusion
system
second
hypothesi
arb
hydrolysi
vivo
follow
intracellular
accumul
cleav
compound
find
support
result
arb
display
optim
activ
administ
hour
primari
hcv
infect
preincub
hour
cell
hcvpp
infect
studi
also
reproduc
notic
arb
inhibit
cell
entri
andor
fusion
concern
hcvpp
happ
suggest
arb
might
display
specif
recognit
key
motif
insid
fusion
protein
lead
inhibit
properti
protein
furthermor
hcvpp
fusion
pronounc
genotyp
genotyp
pseudoparticl
sinc
differ
hcv
genotyp
possess
sequenc
variabl
conceiv
arb
might
differ
affect
fusion
induc
genet
differ
glycoprotein
fusion
assay
liposom
devoid
hcv
receptor
therefor
subtl
chang
envelop
protein
conform
genotyp
might
affect
fusion
infect
sinc
receptor
could
help
conform
rearrang
plasma
membran
cell
sinc
arb
like
abl
enter
number
chemic
interact
lipid
molecul
interact
might
exist
arb
hcv
glycoprotein
well
hydrophob
interact
format
salt
bridg
interact
govern
bind
sever
ligand
protein
eg
hypothesi
test
experiment
present
absenc
hcv
howev
studi
use
recent
describ
genotyp
chimer
infecti
cultur
system
may
provid
insight
mechan
account
possibl
genotypespecif
effect
arb
arbidol
also
exert
clear
inhibitori
effect
hcv
replic
loss
protein
express
declin
rna
level
effect
visibl
week
treatment
cell
contain
replicon
rebound
effect
observ
remov
drug
sinc
replicon
produc
infecti
particl
antivir
effect
arb
system
involv
inhibit
viru
fusion
infect
hcv
replic
complex
associ
endoplasm
reticulum
er
membran
form
membran
web
web
form
via
associ
hcv
nonstructur
protein
er
membran
one
therefor
specul
arbinduc
inhibit
hcv
nonstructur
protein
interact
organel
membran
requir
hcv
replic
might
also
contribut
arb
anti
hcv
action
current
interferonbas
antihcv
therapi
shown
limit
sinc
patient
achiev
sustain
viral
erad
ifn
treatment
number
antivir
strategi
hcv
present
develop
direct
viral
enzym
viral
genom
aim
modul
host
immun
respons
recent
two
group
describ
antihcv
replic
activ
small
molecul
perturb
intracellular
lipid
metabol
sakamoto
cowork
describ
activ
prevent
de
novo
synthesi
sphingolipid
thu
disrupt
associ
hcv
nonstructur
protein
lipid
raft
pezacki
group
studi
anti
hcv
effect
antagonist
peroxisom
proliferatoractiv
receptor
ppar
inhibit
ppar
led
hcv
inhibit
replic
disregul
lipid
metabol
phospholipid
secret
cholesterol
catabol
triglycerid
clearanc
thu
lipid
membran
clearli
central
hcv
lifecycl
step
directli
relat
membran
activ
arbidol
tropism
membran
inhibitori
effect
hcv
entri
fusion
replic
open
promis
perspect
search
new
effici
antihcv
therapi
octadecyl
rhodamin
b
chlorid
felin
endogen
oncoretroviru
sd
sodium
dodecyl
sulfat
measur
record
excit
exc
emiss
em
slit
set
nm
respect
rel
orient
exc
em
polar
respect
arb
absorb
dot
curv
record
ph
fluoresc
emiss
spectra
record
ph
thin
solid
line
ph
thick
solid
line
fluoresc
monitor
use
arb
solut
exc
nm
fluoresc
condit
similar
increas
concentr
deterg
ad
cuvett
contain
arb
pb
buffer
acidifi
ph
equilibr
emiss
spectra
concentr
record
equilibr
fluoresc
intens
obtain
deterg
addit
correct
use
blank
valu
deterg
alon
buffer
plot
percentag
initi
valu
function
final
deterg
concentr
measur
perform
preequilibr
b
variat
fluoresc
quantum
yield
express
ff
f
f
denot
fluoresc
intens
nm
addit
deterg
pc
chol
liposom
respect
biochemistri
author
manuscript
avail
pmc
septemb
